Literature DB >> 25109451

Interferon regulatory factor 8 functions as a tumor suppressor in renal cell carcinoma and its promoter methylation is associated with patient poor prognosis.

Qian Zhang1, Lian Zhang1, LiLi Li2, Zhaohui Wang2, Jianming Ying3, Yu Fan1, Ben Xu1, Lu Wang1, Qianling Liu1, Guangfu Chen4, Qian Tao5, Jie Jin6.   

Abstract

Interferon regulatory factor 8 (IRF8), as a central element of IFN-γ-signaling, plays a critical role in tumor suppression. However, its expression and underlying molecular mechanism remain elusive in renal cell carcinoma (RCC). Here, we examined IRF8 expression and methylation in RCC cell lines and primary tumors, and further assessed its tumor suppressive functions. We found that IRF8 was widely expressed in human normal tissues including kidney, but frequently downregulated by promoter methylation in RCC cell lines. IRF8 methylation was detected in 25% of primary tumors, but not in adjacent non-malignant renal tissues, and associated with higher tumor nuclear grade of RCC. Ectopic expression of IRF8 inhibited colony formation and migration abilities of RCC cells, through inducing cell cycle G2/M arrest and apoptosis. IFN-γ could induce IRF8 expression in RCC cells, together with increased cleaved-PARP. We further found that IRF8 inhibited expression of oncogenes YAP1 and Survivin, as well as upregulated expression of tumor suppressor genes CASP1, p21 and PTEN. Collectively, our data demonstrate that IRF8 as a functional tumor suppressor is frequently methylated in RCC, and IRF8-mediated interferon signaling is involved in RCC pathogenesis.
Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Epigenetic; IRF8; Methylation; Renal carcinoma; Tumor suppressor

Mesh:

Substances:

Year:  2014        PMID: 25109451     DOI: 10.1016/j.canlet.2014.07.040

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  20 in total

1.  Hepatic interferon regulatory factor 8 expression suppresses hepatocellular carcinoma progression and enhances the response to anti-programmed cell death protein-1 therapy.

Authors:  Hongxi Wu; Yan Li; Guangjiang Shi; Shijia Du; Xiaobin Wang; Wanli Ye; Zixuan Zhang; Ya Chu; Shuqian Ma; Dajia Wang; Yuan Li; Zhen Chen; Lutz Birnbaumer; Zhuo Wang; Yong Yang
Journal:  Hepatology       Date:  2022-01-06       Impact factor: 17.298

2.  Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer.

Authors:  Rong Yang; Ting-Ting Cai; Xiao-Jun Wu; Yi-Na Liu; Jia He; Xiao-Shi Zhang; Gang Ma; Jiang Li
Journal:  Immunology       Date:  2018-06-11       Impact factor: 7.397

3.  DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8.

Authors:  Chunyuan Guo; Lirong Pei; Xiao Xiao; Qingqing Wei; Jian-Kang Chen; Han-Fei Ding; Shuang Huang; Guoping Fan; Huidong Shi; Zheng Dong
Journal:  Kidney Int       Date:  2017-07-12       Impact factor: 10.612

4.  Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma.

Authors:  Yulian Xu; Lei Jiang; Jianchen Fang; Rong Fang; Herbert C Morse; Guifang Ouyang; Jeff X Zhou
Journal:  J Cancer       Date:  2015-08-07       Impact factor: 4.207

5.  Frequent epigenetic suppression of tumor suppressor gene glutathione peroxidase 3 by promoter hypermethylation and its clinical implication in clear cell renal cell carcinoma.

Authors:  Qianling Liu; Jie Jin; Jianming Ying; Mengkui Sun; Yun Cui; Lian Zhang; Ben Xu; Yu Fan; Qian Zhang
Journal:  Int J Mol Sci       Date:  2015-05-11       Impact factor: 5.923

6.  MMP3-mediated tumor progression is controlled transcriptionally by a novel IRF8-MMP3 interaction.

Authors:  Debarati Banik; Colleen S Netherby; Paul N Bogner; Scott I Abrams
Journal:  Oncotarget       Date:  2015-06-20

7.  The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features.

Authors:  Lu Wang; Yun Cui; Lian Zhang; Jindong Sheng; Yang Yang; Guanyu Kuang; Yu Fan; Qian Zhang; Jie Jin
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

8.  Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer.

Authors:  Yixiang Zhang; Yeqing Yuan; Pei Liang; Zhaoxia Zhang; Xiaojing Guo; Ligang Xia; Yingying Zhao; Xing-Sheng Shu; Shengkun Sun; Ying Ying; Yingduan Cheng
Journal:  Oncotarget       Date:  2017-07-11

9.  Regulation of cancer epigenomes with a histone-binding synthetic transcription factor.

Authors:  David B Nyer; Rene M Daer; Daniel Vargas; Caroline Hom; Karmella A Haynes
Journal:  NPJ Genom Med       Date:  2017-01-09       Impact factor: 8.617

10.  The epigenetic modifier CHD5 functions as a novel tumor suppressor for renal cell carcinoma and is predominantly inactivated by promoter CpG methylation.

Authors:  Zhenfang Du; Lili Li; Xin Huang; Jie Jin; Suming Huang; Qian Zhang; Qian Tao
Journal:  Oncotarget       Date:  2016-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.